Table 1.
Laboratory and Hormonal Test Results Before (Wk 0) and During Atezolizumab Therapy (Wk 3–11)a
| Test | Wk | Reference Range | ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 3 | 6 | 9 | 11 | 12 | 13 | ||
| Glycemia | 96 | 95 | 149 | 189 | 549 | 180 | 220 | 74–109 mg/dL |
| C-peptide | 0.7 | 0.0 | >1 ng/mL | |||||
| Sodium | 138 | 141 | 133 | 132 | 121 | 132 | 133 | 135–145 mEq/L |
| Potassium | 3.98 | 4.26 | 5.18 | 5.69 | 7.91 | 5.8 | 4.5 | 3.5–5.1 mEq/L |
| Bicarbonate | 25 | 21 | 15 | 26 | 22–30 mmol/L | |||
| Calcium | 9.2 | 8.6–10.2 mg/dL | ||||||
| Creatinine | 1.1 | 0.7–1.2 mg/dL | ||||||
| eGFR | 95 | >90 mL/min | ||||||
| PTH | 26 | 8–40 ng/L | ||||||
| IGF-1 | 157.2 | 164.8 | 49–193 ng/mL | |||||
| PRL | 17.4 | 11.14 | 2–25 ng/mL | |||||
| LH | 6.4 | 1.1 | 1.2 | 1.4–12.7 mUI/mL | ||||
| FSH | 21.4 | 1.3 | 1.3 | 1.3–19.5 mUI/mL | ||||
| Testosterone | 1.5 | 3.2 | 1.75–7.8 μg/L | |||||
| SHBG | 89.7 | 90.1 | 13.0–89.5 nmol/L | |||||
| ACTH | 18 | 21 | 4 | 5 | <50 ng/L | |||
| Cortisol | 8.2 | 6.1 | <0.4 | <0.4 | 6.7–22.6 μg/dL | |||
| Cortisol peak after ACTH test | 0.4 | >18.0 μg/L | ||||||
| Renin | 350.6 | 4.4–46.1 mIU/mL | ||||||
| Aldosterone | 1.2 ng/dL | 2.2–35.3 ng/dL | ||||||
| TSH | 0.98 | 0.76 | 0.69 | 0.72 | 0.60 | 0.40–4.00 μU/mL | ||
| fT4 | 1.35 | 0.96 | 1.21 | 1.24 | 0.83 | 0.7–1.7 ng/dL | ||
| AbTg | <0.1 | <1.0 | <1.0 | <30.0 UI/mL | ||||
| AbTPO | <0.1 | <1.0 | <1.0 | <10.0 UI/mL | ||||
| Anti–TSH-R Ab | 0.11 | < 1.50 UI/L | ||||||
| Anti–21-OH Ab | 89.33 | <0.40 U/mL | ||||||
| Anti–IA2 Ab | 0.0 | 0.0 | <1.0 UI/mL | |||||
| Anti–GAD Ab | 0.0 | 0.0 | <1.0 UI/mL | |||||
| Anti–pituitary Ab | Positive | Negative | ||||||
Abbreviations: Ab, antibody; AbTg, Ab anti-thyroglobulin; AbTPO, Ab anti-thyroperoxydase; eGFR, estimated glomerular filtration rate; fT4, free thyroxine; PRL, prolactin.
a
Examinations were repeated at wk 12 and 13 during insulin and glucocorticoids replacement therapy.